vs
NORTECH SYSTEMS INC（NSYS）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是NORTECH SYSTEMS INC的1.0倍（$30.3M vs $30.3M），NORTECH SYSTEMS INC净利率更高（3.0% vs -221.3%，领先224.3%），REGENXBIO Inc.同比增速更快（43.0% vs 5.9%），NORTECH SYSTEMS INC自由现金流更多（$5.5M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs -5.9%）
Nortech Systems Inc是一家全球电子制造服务提供商，为医疗科技、工业自动化、航空航天国防、交通运输等领域客户提供产品设计、原型制作、规模生产、供应链管理等全链路解决方案，主打符合行业规范的高可靠性电子组件与装配产品。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
NSYS vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.0倍
$30.3M
营收增速更快
RGNX
高出37.1%
5.9%
净利率更高
NSYS
高出224.3%
-221.3%
自由现金流更多
NSYS
多$58.3M
$-52.8M
两年增速更快
RGNX
近两年复合增速
-5.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $30.3M | $30.3M |
| 净利润 | $897.0K | $-67.1M |
| 毛利率 | 16.7% | — |
| 营业利润率 | 3.0% | -190.0% |
| 净利率 | 3.0% | -221.3% |
| 营收同比 | 5.9% | 43.0% |
| 净利润同比 | 160.7% | -31.2% |
| 每股收益（稀释后） | $0.32 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NSYSRGNX
| Q4 25 | $30.3M | $30.3M | ||
| Q3 25 | $30.5M | $29.7M | ||
| Q2 25 | $30.7M | $21.4M | ||
| Q1 25 | $26.9M | $89.0M | ||
| Q4 24 | $28.6M | $21.2M | ||
| Q3 24 | $31.4M | $24.2M | ||
| Q2 24 | $33.9M | $22.3M | ||
| Q1 24 | $34.2M | $15.6M |
净利润NSYSRGNX
| Q4 25 | $897.0K | $-67.1M | ||
| Q3 25 | $-146.0K | $-61.9M | ||
| Q2 25 | $313.0K | $-70.9M | ||
| Q1 25 | $-1.3M | $6.1M | ||
| Q4 24 | $-1.5M | $-51.2M | ||
| Q3 24 | $-739.0K | $-59.6M | ||
| Q2 24 | $157.0K | $-53.0M | ||
| Q1 24 | $765.0K | $-63.3M |
毛利率NSYSRGNX
| Q4 25 | 16.7% | — | ||
| Q3 25 | 16.5% | — | ||
| Q2 25 | 15.8% | — | ||
| Q1 25 | 11.4% | — | ||
| Q4 24 | 9.9% | 70.2% | ||
| Q3 24 | 12.2% | 48.8% | ||
| Q2 24 | 13.6% | 52.5% | ||
| Q1 24 | 15.9% | 72.6% |
营业利润率NSYSRGNX
| Q4 25 | 3.0% | -190.0% | ||
| Q3 25 | 3.1% | -176.3% | ||
| Q2 25 | 2.4% | -296.3% | ||
| Q1 25 | -6.0% | 13.6% | ||
| Q4 24 | -4.3% | -242.1% | ||
| Q3 24 | -1.5% | -256.6% | ||
| Q2 24 | 1.0% | -251.3% | ||
| Q1 24 | 3.4% | -408.8% |
净利率NSYSRGNX
| Q4 25 | 3.0% | -221.3% | ||
| Q3 25 | -0.5% | -208.3% | ||
| Q2 25 | 1.0% | -331.8% | ||
| Q1 25 | -4.9% | 6.8% | ||
| Q4 24 | -5.2% | -241.3% | ||
| Q3 24 | -2.4% | -246.3% | ||
| Q2 24 | 0.5% | -237.7% | ||
| Q1 24 | 2.2% | -405.4% |
每股收益（稀释后）NSYSRGNX
| Q4 25 | $0.32 | $-1.30 | ||
| Q3 25 | $-0.05 | $-1.20 | ||
| Q2 25 | $0.12 | $-1.38 | ||
| Q1 25 | $-0.48 | $0.12 | ||
| Q4 24 | $-0.51 | $-0.99 | ||
| Q3 24 | $-0.27 | $-1.17 | ||
| Q2 24 | $0.05 | $-1.05 | ||
| Q1 24 | $0.26 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.7M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $34.5M | $102.7M |
| 总资产 | $71.9M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资NSYSRGNX
| Q4 25 | $1.7M | $230.1M | ||
| Q3 25 | $1.3M | $274.2M | ||
| Q2 25 | $652.0K | $323.3M | ||
| Q1 25 | $1.2M | $267.9M | ||
| Q4 24 | $916.0K | $234.7M | ||
| Q3 24 | $1.2M | $255.5M | ||
| Q2 24 | $1.5M | $290.4M | ||
| Q1 24 | $4.0M | $338.7M |
股东权益NSYSRGNX
| Q4 25 | $34.5M | $102.7M | ||
| Q3 25 | $33.4M | $161.5M | ||
| Q2 25 | $33.4M | $213.7M | ||
| Q1 25 | $32.8M | $274.2M | ||
| Q4 24 | $34.0M | $259.7M | ||
| Q3 24 | $35.7M | $301.4M | ||
| Q2 24 | $36.1M | $348.3M | ||
| Q1 24 | $36.0M | $390.7M |
总资产NSYSRGNX
| Q4 25 | $71.9M | $453.0M | ||
| Q3 25 | $74.8M | $525.2M | ||
| Q2 25 | $74.8M | $581.0M | ||
| Q1 25 | $73.5M | $490.9M | ||
| Q4 24 | $72.4M | $466.0M | ||
| Q3 24 | $77.0M | $519.1M | ||
| Q2 24 | $76.3M | $569.4M | ||
| Q1 24 | $75.5M | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $5.6M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $5.5M | $-52.8M |
| 自由现金流率自由现金流/营收 | 18.0% | -174.0% |
| 资本支出强度资本支出/营收 | 0.5% | 1.7% |
| 现金转化率经营现金流/净利润 | 6.25× | — |
| 过去12个月自由现金流最近4个季度 | $2.1M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流NSYSRGNX
| Q4 25 | $5.6M | $-52.3M | ||
| Q3 25 | $-92.0K | $-56.0M | ||
| Q2 25 | $157.0K | $-49.3M | ||
| Q1 25 | $-2.9M | $33.6M | ||
| Q4 24 | $793.0K | $-31.6M | ||
| Q3 24 | $-1.6M | $-40.5M | ||
| Q2 24 | $-4.3M | $-45.5M | ||
| Q1 24 | $2.8M | $-55.5M |
自由现金流NSYSRGNX
| Q4 25 | $5.5M | $-52.8M | ||
| Q3 25 | $-242.0K | $-56.5M | ||
| Q2 25 | $58.0K | $-49.7M | ||
| Q1 25 | $-3.2M | $32.6M | ||
| Q4 24 | $503.0K | $-32.7M | ||
| Q3 24 | $-1.6M | $-40.9M | ||
| Q2 24 | $-4.6M | $-46.0M | ||
| Q1 24 | $2.1M | $-56.0M |
自由现金流率NSYSRGNX
| Q4 25 | 18.0% | -174.0% | ||
| Q3 25 | -0.8% | -189.9% | ||
| Q2 25 | 0.2% | -232.8% | ||
| Q1 25 | -11.9% | 36.6% | ||
| Q4 24 | 1.8% | -154.2% | ||
| Q3 24 | -5.2% | -168.9% | ||
| Q2 24 | -13.5% | -206.2% | ||
| Q1 24 | 6.1% | -358.5% |
资本支出强度NSYSRGNX
| Q4 25 | 0.5% | 1.7% | ||
| Q3 25 | 0.5% | 1.7% | ||
| Q2 25 | 0.3% | 1.8% | ||
| Q1 25 | 1.0% | 1.2% | ||
| Q4 24 | 1.0% | 5.1% | ||
| Q3 24 | 0.1% | 1.3% | ||
| Q2 24 | 0.8% | 2.1% | ||
| Q1 24 | 2.2% | 3.6% |
现金转化率NSYSRGNX
| Q4 25 | 6.25× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.50× | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -27.30× | — | ||
| Q1 24 | 3.70× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NSYS
| Medical Imaging | $11.4M | 37% |
| Medical Device | $8.0M | 26% |
| Industrial | $7.3M | 24% |
| Aerospace And Defense | $3.7M | 12% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
